HK1243929A1 - Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合 - Google Patents

Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合

Info

Publication number
HK1243929A1
HK1243929A1 HK18103426.8A HK18103426A HK1243929A1 HK 1243929 A1 HK1243929 A1 HK 1243929A1 HK 18103426 A HK18103426 A HK 18103426A HK 1243929 A1 HK1243929 A1 HK 1243929A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
bruton
tyrosine kinase
combinations
tlr
Prior art date
Application number
HK18103426.8A
Other languages
English (en)
Inventor
貝蒂．Y．張
達林．博普雷
旭平．郭
Original Assignee
藥品循環有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 藥品循環有限責任公司 filed Critical 藥品循環有限責任公司
Publication of HK1243929A1 publication Critical patent/HK1243929A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18103426.8A 2014-11-17 2018-03-12 Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合 HK1243929A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080921P 2014-11-17 2014-11-17
US201562127740P 2015-03-03 2015-03-03
PCT/US2015/061091 WO2016081460A1 (en) 2014-11-17 2015-11-17 Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations

Publications (1)

Publication Number Publication Date
HK1243929A1 true HK1243929A1 (zh) 2018-07-27

Family

ID=56014455

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103426.8A HK1243929A1 (zh) 2014-11-17 2018-03-12 Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合

Country Status (11)

Country Link
US (1) US20170354655A1 (zh)
EP (1) EP3220912A4 (zh)
JP (1) JP2017533944A (zh)
CN (1) CN106999495A (zh)
AU (1) AU2015350136A1 (zh)
BR (1) BR112017010262A2 (zh)
CA (1) CA2966542A1 (zh)
HK (1) HK1243929A1 (zh)
MX (1) MX2017006464A (zh)
TW (1) TW201628622A (zh)
WO (1) WO2016081460A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス， インコーポレイテッド 毒性アルデヒド関連疾患および処置
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
CN110272417B (zh) * 2019-06-18 2021-07-13 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用
CN110305128B (zh) * 2019-07-31 2021-08-24 桂林医学院 5-氨基苯并[b][1,8]萘啶类化合物的制备方法和应用
CA3175856A1 (en) * 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146879A2 (en) * 2010-05-20 2011-11-24 University Of Rochester Methods and compositions related to modulating autophagy
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
NZ772688A (en) * 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20140206681A1 (en) * 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
US20160022683A1 (en) * 2013-03-14 2016-01-28 Pharmacyclics Llc Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
CA2908375A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics Llc Ibrutinib combination therapy

Also Published As

Publication number Publication date
US20170354655A1 (en) 2017-12-14
TW201628622A (zh) 2016-08-16
JP2017533944A (ja) 2017-11-16
MX2017006464A (es) 2018-08-09
EP3220912A4 (en) 2018-06-20
BR112017010262A2 (pt) 2018-07-03
CA2966542A1 (en) 2016-05-26
AU2015350136A1 (en) 2017-05-25
WO2016081460A1 (en) 2016-05-26
CN106999495A (zh) 2017-08-01
EP3220912A1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
HK1256857A1 (zh) 多氟化合物作為布魯頓酪氨酸激酶抑制劑
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL255831A (en) Inhibitors of bruton's tyrosine kinase
HK1243929A1 (zh) Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合
EP3177366A4 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
IL289766A (en) tfpi inhibitory antibodies and their uses
IL245042A0 (en) Treatment with proton tyrosine kinase inhibitors and immunotherapy
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
IL244492A0 (en) Broton tyrosine kinase inhibitors
HUE045477T2 (hu) Imidazolonilkinolinok és ezek alkalmazása ATM kináz inhibitorként
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
EP3141546A4 (en) Inhibitor of bruton's tyrosine kinase
EP2968341A4 (en) COMBINATIONS OF BURTON TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS
EP3159340A4 (en) New bruton's tyrosine kinase inhibitor
IL287433A (en) Combination of anti-cd19 antibody and proton tyrosine kinase inhibitor and its uses
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
HK1249737A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的溶劑化形式
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
EP3328380A4 (en) INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
GB201721668D0 (en) Extract and use thereof